Checkpoint Therapeutics, Inc , clinical-stage immunotherapy and targeted oncology company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers.
infoCheckpoint Therapeutics is a micro cap stock with a total market cap of 48.97M.
infoThey trade on the NASDAQ and had their IPO 6 years and 8 months ago.
infoCheckpoint Therapeutics currently employs 24 people.
infoAs of Wednesday, Aug 23 2023, Checkpoint Therapeutics’s share price is $2.16.
News Relating to Checkpoint Therapeutics
Seeking Alpha
Checkpoint: PDUFA Date Catalyst Makes This A Must Watch
Tuesday Aug 01 2023 at 19:01
A PDUFA date of January 3, 2024 has been established by which FDA will decide upon by then whether or not cosibelimab should be approved for the treatment of cSCC. It is said that the cutaneous squamous cell carcinoma market in the U.S. alone could reach $1.6 billion. Company plans to compete with other PD-1/PD-L1 inhibitors in terms of mechanism of action, which gives cosibelimab an improved safety profile over other drugs in the same class.
Seeking Alpha
Checkpoint Therapeutics: Cosibelimab Data Bolsters Case For Dual-Approval In cSCC
Sunday Jul 30 2023 at 04:19
Checkpoint Therapeutics announced updated, longer-term data for cosibelimab from their pivotal trial in locally advanced and metastatic cutaneous squamous cell carcinoma “cSCC”. The data revealed improved response over time with higher complete response rates compared to previous readouts. The responses were durable with the median duration of response not yet reached. Checkpoint believes cosibelimab has a shot at a $1.6B market opportunity, yet, CKPT continues to trade in the gutter with a market cap of around $61M.
InvestorPlace
3 Stocks With 1,000% Upside Potential
Sunday May 21 2023 at 10:03
If you’re a risk taker on the lookout for stocks with 1000% upside potential, you’d have to venture into speculative territory. It is difficult to find analyst ratings with such a high upside potential unless catalysts could propel the stock that high.
InvestorPlace
3 Penny Stocks That Could Make You a Millionaire by 2025
Thursday May 11 2023 at 16:40
Penny stocks have had a great start this year, but with uncertainty starting to rear its head again, investors have started to choose safer options instead. Indeed, the underlying businesses of most penny stocks are loss-making startups that depend on external sources to survive in the long run.
Seeking Alpha
Checkpoint Therapeutics: An Updated Analysis
Tuesday Jan 10 2023 at 13:40
We are checking back in on a small developmental company called Checkpoint Therapeutics, Inc. The company is planning to submit a BLA targeting two indications for its lead product candidate cosibelimab later this month.
PennyStocks
5 Penny Stocks With Explosive Price Targets & Buy Ratings From Analysts
Tuesday Dec 27 2022 at 13:52
Analysts Say These Are Penny Stocks To Buy But Are They Worth The Risk? The post 5 Penny Stocks With Explosive Price Targets & Buy Ratings From Analysts appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
CNBC Television
Wedbush’s Dan Ives offers his bullish outlook on tech in 2023
Monday Dec 12 2022 at 18:28
Dan Ives, Wedbush analyst, joins ‘Closing Bell: Overtime’ to discuss why he believes there will be a tech rebound.
GlobeNewsWire
Checkpoint Therapeutics to Participate in Two Upcoming Investor Conferences
Thursday Sep 22 2022 at 08:30
WALTHAM, Mass., Sept. 22, 2022 (GLOBE NEWSWIRE) — Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDAQ: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced that James Oliviero, President and Chief Executive Officer, will participate in two upcoming investor conferences. Details are as follows:
GlobeNewsWire
Checkpoint Therapeutics to Participate in Two Upcoming Investor Conferences
Thursday Sep 08 2022 at 08:15
WALTHAM, Mass., Sept. 08, 2022 (GLOBE NEWSWIRE) — Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDAQ: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced that James Oliviero, President and Chief Executive Officer, will participate in two upcoming investor conferences. Details are as follows:
Benzinga
Checkpoint’ Cancer Therapy Shows Almost 55% Response Rate In Skin Cancer Patients
Thursday Jun 16 2022 at 09:40
Checkpoint Therapeutics Inc (NASDAQ: CKPT) announced positive interim efficacy results from its registration-enabling trial of cosibelimab, in patients with locally advanced cutaneous squamous cell carcinoma (cSCC) who are not candidates for curative surgery or radiation. The.
GlobeNewsWire
Checkpoint Therapeutics to Participate in the H.C. Wainwright Global Investment Conference
Thursday May 19 2022 at 08:30
WALTHAM, Mass., May 19, 2022 (GLOBE NEWSWIRE) — Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDAQ: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced that James Oliviero, President and Chief Executive Officer, will present a company overview at the H.C. Wainwright Global Investment Conference, on Wednesday, May 25, 2022, at 3:00 p.m. ET. Checkpoint management will also participate in one-on-one meetings during the conference.
PennyStocks
Insiders Are Dumping These Penny Stocks, Look Out Below Or Buy The Dip?
Tuesday Apr 26 2022 at 14:57
Time to sell these penny stocks? The post Insiders Are Dumping These Penny Stocks, Look Out Below Or Buy The Dip?
Seeking Alpha
Checkpoint Therapeutics: Potential Upside Based On Marketing Application Submissions
Monday Apr 18 2022 at 14:15
Cosibelimab BLA submission to FDA for cutaneous squamous cell carcinoma is expected in late 2022, with MAA to the European Medicines Agency shortly thereafter. Cosibelimab regulatory applications are possible because of obtaining a confirmed objective response rate of 47.4% in patients with cutaneous squamous cell carcinoma.
GlobeNewsWire
Checkpoint Therapeutics to Present at the Virtual Fortress Biotech R&D Summit Hosted by B. Riley Securities
Monday Apr 04 2022 at 08:15
WALTHAM, Mass., April 04, 2022 (GLOBE NEWSWIRE) — Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDAQ: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced that members of Checkpoint’s management team will participate in the two-day Fortress Biotech (“Fortress”) Virtual R&D Summit taking place on Tuesday, April 5, 2022 and Wednesday, April 6, 2022. The Summit will be hosted by the B. Riley Securities’ Healthcare Equity Research team and will feature multiple programs from Fortress’ diversified pipeline.
Seeking Alpha
Checkpoint Therapeutics: Another Buying Opportunity Following Cosibelimab’s Impressive Topline Results
Friday Jan 28 2022 at 12:26
Checkpoint Therapeutics: Another Buying Opportunity Following Cosibelimab’s Impressive Topline Results
Pulse2
Checkpoint Therapeutics Stock (CKPT): Why The Price Substantially Went Up Today
Tuesday Jan 25 2022 at 11:03
The stock price of Checkpoint Therapeutics Inc (NASDAQ: CKPT) increased by over 13% during intraday trading. This is why it happened.
The Motley Fool
Why Checkpoint Therapeutics Stock Is Heating Up Today
Tuesday Jan 25 2022 at 10:06
Based on its latest clinical trial data, this small-cap biotech could have a best-in-class treatment for advanced skin cancer on the way.
Seeking Alpha
Checkpoint Therapeutics: Pullback Provides Opportunity To Add Ahead Of Cosibelimab’s Data Readout
Friday Nov 26 2021 at 00:51
Checkpoint Therapeutics expects to report top-line results before year-end, which could determine if Cosibelimab is ready for regulatory submission that could lead to an approval and commercial launch in 2023. Volatility has the share price, which is making big moves in both directions as we move closer to year-end. Investors need to have a game plan.
GlobeNewsWire
Checkpoint Therapeutics to Participate in Two Upcoming Investor Conferences
Thursday Sep 09 2021 at 08:30
WALTHAM, Mass., Sept. 09, 2021 (GLOBE NEWSWIRE) — Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDAQ: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced that James Oliviero, President and Chief Executive Officer, will participate in two upcoming investor conferences. Details are as follows:
GlobeNewsWire
Checkpoint Therapeutics Reports Second Quarter 2021 Financial Results
Thursday Aug 05 2021 at 16:30
NEW YORK, Aug. 05, 2021 (GLOBE NEWSWIRE) — Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDAQ: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced financial results for the second quarter ended June 30, 2021.
Seeking Alpha
Checkpoint Therapeutics: Amassing A Position Ahead Of Cosibelimab Data
Tuesday Jul 13 2021 at 23:16
Checkpoint Therapeutics: Amassing A Position Ahead Of Cosibelimab Data
GlobeNewsWire
Checkpoint Therapeutics to Participate in the Ladenburg Thalmann 2021 Healthcare Conference
Thursday Jul 08 2021 at 08:30
NEW YORK, July 08, 2021 (GLOBE NEWSWIRE) — Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDAQ: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced that James Oliviero, President and Chief Executive Officer, will participate in the Ladenburg Thalmann 2021 Healthcare Conference, taking place July 13-14, 2021. The company will present a corporate update on Wednesday, July 14, 2021, at 11:30 a.m. ET and will also participate in one-on-one meetings during the conference. A webcast of the company’s presentation will be available on the Events page, located within the Investors section of Checkpoint’s website, https://ir.checkpointtx.com/event-calendar/default.aspx, for approximately 30 days after the meeting.
24/7 Wall Street
4 Biotech and Life Sciences Stocks Trading Under $10 With Gigantic Upside Potential
Saturday Jun 19 2021 at 06:15
While most of Wall Street focuses on large-cap and mega-cap stocks, as they provide a degree of safety and liquidity, many investors are limited in the number of shares they can buy.
The Motley Fool
Why Checkpoint Therapeutics Skyrocketed Today
Wednesday Jun 09 2021 at 18:01
One analyst becomes a fervent believer in the company’s stock.
Pulse2
AEMD, CTEK, AEHL, AMSWA, CKPT, CLNE, SPI, ATOM, PUBM, IMH Stock Prices Gain Intraday
Wednesday Jun 09 2021 at 14:33
The stock prices of AEMD, CTEK, AEHL, AMSWA, CKPT, CLNE, SPI, ATOM, PUBM, and IMH have noticeably gained today. The post AEMD, CTEK, AEHL, AMSWA, CKPT, CLNE, SPI, ATOM, PUBM, IMH Stock Prices Gain Intraday appeared first on Pulse 2.0.
24/7 Wall Street
Lordstown, Morgan Stanley, ResMed and More Wednesday Afternoon Analyst Calls
Wednesday Jun 09 2021 at 12:20
With the trading day about halfway over, the markets were trading sideways yet again, and it seems like the major averages may be stuck on this plateau.
Pulse2
CKPT Stock Price: Over 30% Increase Pre-Market Explanation
Wednesday Jun 09 2021 at 09:02
The stock price of Checkpoint Therapeutics Inc (NASDAQ: CKPT) increased by over 30% pre-market. This is why it happened.
PennyStocks
4 Meme Penny Stocks To Watch As DogeCoin Rises
Saturday May 08 2021 at 19:16
Meme penny stocks are a budding sector; have you heard of these 4? The post 4 Meme Penny Stocks To Watch As DogeCoin Rises appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
GlobeNewsWire
Checkpoint Therapeutics Reports Full-Year 2020 Financial Results and Recent Corporate Highlights
Tuesday Mar 09 2021 at 16:30
NEW YORK, March 09, 2021 (GLOBE NEWSWIRE) — Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDAQ: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced financial results for the full-year ended December 31, 2020 and recent corporate highlights.
GlobeNewsWire
Checkpoint Therapeutics Announces Formation of Scientific Advisory Board
Monday Mar 01 2021 at 08:30
Members include preeminent clinical and scientific thought leaders in oncology Members include preeminent clinical and scientific thought leaders in oncology
Checkpoint Therapeutics Bankruptcy Risk
The Altman Z-score is a formula that measures a company’s financial health and bankruptcy risk. It assigns a numerical score based on various financial ratios. The Z-score is divided into different zones. If the Z-score is above 2.99, it indicates a lower bankruptcy risk, classifying the company as ‘safe’ or ‘non-distressed’. If the score falls below 1.81, it suggests a higher risk, indicating potential financial distress or bankruptcy. The range between 1.81 and 2.99 is called the ‘gray zone’ or zone of ambiguity.
Learn more at Investopediaopen_in_new
Checkpoint Therapeutics’s Altman Z-score is -75.39 which is in the distress zone. This indicates a higher risk of financial distress and potential bankruptcy for the company. It can serve as a warning sign of significant financial challenges, requiring careful consideration by potential investors.
Derived from SEC.GOV filing dataopen_in_new
Checkpoint Therapeutics Insider Trading
Insider trading is when individuals employed by a company buy or sell its securities following legal procedures and regulations. Company executives, directors, and employees may be permitted to buy or sell shares if they follow specific rules, such as filing a Form 4 with the SEC within two business days.
Learn more at Investopediaopen_in_new
Over the last 3 months, there has been no insider trading in Checkpoint Therapeutics.
Derived from SEC.GOV filing dataopen_in_new
Debt & Income Analysis
Income quality measures a company’s operating cash flow to net income ratio. It helps investors and analysts assess the sustainability of a company’s earnings. A high QIR indicates strong cash flows, while a low QIR may indicate non-operating activities driving net income.
Learn more at WallStreetPrepopen_in_new
Checkpoint Therapeutics’s Income Quality of 0.72 is in line with its Industry Group of 0.69 (4.3% greater)
Checkpoint Therapeutics’s Income Quality of 0.72 is in line with its Major Industry Group of 0.71 (1.4% greater)
Checkpoint Therapeutics’s Income Quality of 0.72 is in line with its Sector of 0.75 (-4.0% lower)
Derived from SEC.GOV filing dataopen_in_new
Current ratio measures a company’s ability to pay off short-term debt with its current assets (assets that a company expects to use up or convert to cash within a year). It represents the $ amount of current assets a company has for every $1 of short-term debt. A high current ratio above 1.0 indicates that a company can meet its short-term obligations, while a low current ratio below 1.0 suggests difficulty.
Learn more at Investopediaopen_in_new
Checkpoint Therapeutics’s Current Ratio of 0.26 is lower than its Industry Group of 4.76 (-94.5% lower)
Checkpoint Therapeutics’s Current Ratio of 0.26 is lower than its Major Industry Group of 4.32 (-94.0% lower)
Checkpoint Therapeutics’s Current Ratio of 0.26 is lower than its Sector of 2.6 (-90.0% lower)
Derived from SEC.GOV filing dataopen_in_new
Value Analysis
PE ratio (price-to-earnings), measures a company’s stock price relative to its earnings per share. It helps investors evaluate whether its stock is overvalued or undervalued. A higher PE ratio indicates that investors are willing to pay more for a company’s earnings, while a lower PE ratio (above zero) suggests the company could be undervalued.
Learn more at Investopediaopen_in_new
Cannot compare a negative PE Ratio (-0.89 & -1.27)
Cannot compare a negative PE Ratio (-0.89 & -1.1)
Cannot compare a negative PE Ratio (-0.89 & -0.4)
Derived from SEC.GOV filing dataopen_in_new
The PB ratio (price-to-book), measures a company’s stock price relative to its book value (net value of a company’s assets reported on its balance sheet, after subtracting debt) per share. It is used to evaluate a company’s valuation, with a lower PB ratio (above zero) indicating a lower valuation and a higher PB ratio suggesting overvaluation.
Learn more at Investopediaopen_in_new
Cannot compare a negative PB Ratio (-2.1 & 1.34)
Cannot compare a negative PB Ratio (-2.1 & 1.4)
Cannot compare a negative PB Ratio (-2.1 & 1.62)
Derived from SEC.GOV filing dataopen_in_new
Efficiency Analysis
ROE (Return on Equity), is a financial ratio that measures a company’s profitability relative to its shareholders’ equity (the amount of value in a company that belongs to the people who own shares). It indicates how efficiently a company generates profits per unit of equity invested. A high ROE suggests effective use of equity, while a low ROE indicates inefficiency.
Learn more at Investopediaopen_in_new
Checkpoint Therapeutics’s ROE of 2.37 is greater than its Industry Group of -0.44 (638.6% greater)
Checkpoint Therapeutics’s ROE of 2.37 is greater than its Major Industry Group of -0.38 (723.7% greater)
Checkpoint Therapeutics’s ROE of 2.37 is greater than its Sector of -0.03 (8000.0% greater)
Derived from SEC.GOV filing dataopen_in_new
ROCE (Return on Capital Employed), is a financial ratio that measures a company’s profitability relative to the amount of capital invested in its operations. It indicates how well a company is generating profits from its capital investments. A high ROCE suggests effective use of capital, while a low ROCE indicates inefficiency.
Learn more at Investopediaopen_in_new
Checkpoint Therapeutics’s ROCE of 2.65 is greater than its Industry Group of -0.42 (731.0% greater)
Checkpoint Therapeutics’s ROCE of 2.65 is greater than its Major Industry Group of -0.37 (816.2% greater)
Checkpoint Therapeutics’s ROCE of 2.65 is greater than its Sector of -0.04 (6725.0% greater)
Derived from SEC.GOV filing dataopen_in_new